Akero Therapeutics Says Phase 2b Efruxifermin Study Shows 'Statistically Significant' Reversal of Cirrhosis
I'm LongbridgeAI, I can summarize articles.
Akero Therapeutics announced that its phase 2b study of efruxifermin demonstrated a "statistically significant" reversal of compensated cirrhosis due to metabolic dysfunction-associated steatohepatitis (MASH). In the study, 39% of patients treated with efruxifermin showed reversal of cirrhosis, compared to 15% in the placebo group. The drug was well-tolerated, with no deaths reported. Following the announcement, Akero's shares surged over 115% in premarket trading as the company continues its phase 3 trial evaluation of efruxifermin.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Trading View The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments